Stem Point Capital LP Denali Therapeutics Inc. Transaction History
Stem Point Capital LP
- $401 Billion
- Q4 2024
A detailed history of Stem Point Capital LP transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Stem Point Capital LP holds 584,328 shares of DNLI stock, worth $9.75 Million. This represents 2.97% of its overall portfolio holdings.
Number of Shares
584,328
Previous 282,050
107.17%
Holding current value
$9.75 Million
Previous $8.22 Billion
44.94%
% of portfolio
2.97%
Previous 2.46%
Shares
3 transactions
Others Institutions Holding DNLI
# of Institutions
240Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$220 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$206 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$201 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$164 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$91.4 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.24B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...